South Africa’s supplement crackdown risks R22bn health industry

Health supplements are products such as vitamins, minerals, probiotics, amino acids, collagen, omega oils, protein powders, herbal preparations and traditional formulations. They are commonly used for nutrition, general wellbeing and health maintenance. They still need standards for quality, safety, labelling and truthful claims.

Pharmaceutical medicines are not automatically the same as these lower-risk products. A vitamin C tablet, magnesium supplement, protein powder or omega-3 capsule is not a prescription medicine. The key difference is the product’s intended use, ingredients and level of risk, not simply its health-related purpose.

That distinction matters because regulation carries costs. Lower-risk supplements may need oversight, but pharmaceutical-level requirements can raise compliance expenses, increase prices and reduce consumer choice. South Africa’s own framework recognises different risk levels, with health supplements limited to low-risk indications and substances. Regulation should therefore match risk rather than treat every health product as a medicine.

South Africa has been edging toward a regulatory framework that treats many natural health and wellness products as medicines. The proposed direction covers vitamins, minerals, probiotics, amino acids, collagen, omega oils, protein powders, herbal preparations and traditional formulations.

These products are widely used for nutrition, general wellbeing and health maintenance. They should meet clear standards for quality, safety, labelling and truthful claims. The central concern is proportionality. A low-risk supplement may need oversight, but it may not need the same regulatory burden as a pharmaceutical medicine.

The change matters because medicines-style rules can require extensive documentation, testing, specialist expertise, registration and continuing regulatory costs. Large companies may absorb these demands, but many smaller businesses may struggle. South Africa’s court history also matters: the Supreme Court of Appeal found that 2017 regulations could not apply to products outside the legal definitions of medicines or scheduled substances.

South Africa’s natural health and wellness sector contributes R22 billion to the economy. The article also warns that thousands of jobs are at stake if lower-risk products face unnecessarily heavy regulation. That makes the issue much larger than a technical dispute about product registration.

The sector includes companies making supplements and wellness products, as well as ingredient suppliers, packaging companies, laboratories and logistics providers. Large manufacturers may have resources to manage extensive compliance demands. Many small and medium-sized businesses may not. Their survival can depend on the cost and complexity of the regulatory system.

The article does not provide a separate count for each business type or a detailed breakdown of formal retail employment. It does make the broader economic risk clear. Pharmaceutical-style documentation, testing, specialist expertise and ongoing costs could affect the entire supply chain. Higher costs or fewer products could then affect consumers and the businesses supporting this sector.

Heavy regulation can produce effects far beyond paperwork. When lower-risk products face pharmaceutical-level requirements, compliance costs rise. Those costs can be passed to consumers through higher prices. Businesses may also decide that some products are no longer worth making or selling.

The mechanism is straightforward. Requirements may include extensive technical documents, testing, specialist expertise, registration processes and continuing regulatory expenses. Large companies may absorb them more easily. Many small and medium-sized enterprises may struggle, leading to fewer businesses, fewer products or less competition. Consumer choice could shrink as a result.

The article identifies these risks for the sector and its supply chain, including ingredient suppliers, packaging companies, laboratories and logistics providers. It warns that thousands of jobs are at stake. It does not give a separate forecast for formal retail, so the supported conclusion is broader: costs and product availability could affect businesses and consumers across the market.

The South African Health Products Regulatory Authority, or Sahpra, is the regulator involved in South Africa’s health-products framework. The article presents its risk distinction as an important principle. Products should not all receive the same regulatory burden merely because they relate to health or wellbeing.

Sahpra’s framework identifies health supplements as products limited to low-risk indications and substances. Higher-risk complementary medicines may require stronger evidence. In practical terms, the level of scrutiny should rise when the possible harm or therapeutic claim becomes greater. This creates a graduated approach rather than one blanket rule.

That distinction matters for vitamins, minerals, probiotics, herbal preparations and similar products. They still need oversight for quality, safety, labelling and truthful claims. But the article argues that lower-risk products should not automatically face pharmaceutical-level obligations. Sahpra also stated after the court judgment that draft amendments were being developed to align the framework with the court’s findings.

The Supreme Court of Appeal considered the case Minister of Health and Another versus Alliance of Natural Health Products (South Africa). It held that the 2017 regulations were illegal to the extent that they applied to complementary medicines and health supplements that were not “medicines” or “Scheduled substances” under the Medicines and Related Substances Act.

The key mechanism was legal authority. A regulator cannot automatically use a medicines framework for every product associated with health. The products first had to fall within the Act’s legal definitions. If they did not, the 2017 regulations could not lawfully impose that medicines-based system on them.

The judgment forced a rethink of the regulatory approach. Afterward, Sahpra stated that draft amendments were being developed to align the framework with the court findings. The article presents this history as a warning against regulatory over-reach, while still supporting firm action against unsafe, adulterated, unlawful or misleading products.

Risk-based regulation matters because products differ in their potential harm, use and claims. A framework should impose stronger evidence and controls when risks are higher, while avoiding unnecessary pharmaceutical burdens for lower-risk supplements. This can protect consumers without making compliance so costly that smaller businesses or product choice suffer.

The article gives several examples. The European Union has a dedicated food-supplement framework covering permitted vitamins and minerals and protection against misleading information. India regulates supplements and nutraceuticals through food safety rules covering probiotics, prebiotics and functional foods. Brazil uses a dedicated food-supplement framework under Anvisa. Canada separately regulates vitamins, minerals, probiotics, herbal remedies and amino acids.

Canada’s system includes product licensing, manufacturing standards, labelling and adverse-reaction reporting. It is also being reviewed to reduce regulatory burden and improve proportionality. These examples show that oversight does not require every natural health product to be placed in a conventional pharmaceutical model.